Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung Cancer

5 Dec 2024

Abstract excerpt

Lurbinectedin is a selective inhibitor of oncogenic transcription approved for the treatment of adult patients with metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy. Preclinical data provide evidence for lurbinectedin exerting its actions in a unique manner that involves oncogenic transcription inhibition, DNA damage, reshaping of the tumor microenvironment, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Research Studies
Share to Neuroendocrine Tumor Research Advances
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39636909
DOI: 10.1158/1535-7163.mct-24-0050

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung CancerPMID 39636909Read ↗

Targeting DNA Damage Response-Mediated Resistance in Non-Small Cell Lung Cancer: From Mechanistic Insights to Drug DevelopmentSemantic proximity Read ↗

Small cell lung cancer: Novel treatments beyond immunotherapySemantic proximity Read ↗

Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and ChallengesSemantic proximity Read ↗

Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancerSemantic proximity Read ↗

The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung CancerSemantic proximity Read ↗

Regulation of cisplatin resistance in lung cancer by epigenetic mechanismsSemantic proximity Read ↗

Signal pathways and precision therapy of small-cell lung cancerSemantic proximity Read ↗

Targeted and cytotoxic inhibitors used in the treatment of lung cancersSemantic proximity Read ↗

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.Semantic proximity Read ↗

Nanomedicine Strategies for Management of Drug Resistance in Lung CancerSemantic proximity Read ↗

Modern therapies of nonsmall cell lung cancerSemantic proximity Read ↗

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.